# Safety and Efficacy Study of PRI-724 Plus Gemcitabine in Subjects With Advanced or Metastatic Pancreatic Adenocarcinoma

> **NCT01764477** · PHASE1 · COMPLETED · sponsor: **Prism Pharma Co., Ltd.** · enrollment: 20 (actual)

## Conditions studied

- Advanced Pancreatic Cancer
- Metastatic Pancreatic Cancer
- Pancreatic Adenocarcinoma

## Interventions

- **DRUG:** PRI-724

## Key facts

- **NCT ID:** NCT01764477
- **Lead sponsor:** Prism Pharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04
- **Primary completion:** 2015-10
- **Final completion:** 2015-10
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2017-08-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01764477

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01764477, "Safety and Efficacy Study of PRI-724 Plus Gemcitabine in Subjects With Advanced or Metastatic Pancreatic Adenocarcinoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01764477. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*